<?xml version='1.0' encoding='UTF-8' ?>
<ec-patent-document file='EC_SP17028310_20180329.xml' country='EC' doc-number='SP17028310' kind='A' date-published='20180329' lang='ES' date-produced='20190116'>
<bibliographic-data id='bibl' doc-number='SP17028310' country='EC' lang='es'>
<publication-reference><document-id ><country>EC</country><doc-number>SP17028310</doc-number><kind>A</kind><date>20180329</date></document-id></publication-reference>
<classification-ipcr><classification-ipc sequence='1'><section> </section><class> </class><subclass> </subclass><main-group> </main-group><subgroup> </subgroup><edition> </edition><ipc-version-indicator><date> </date></ipc-version-indicator><classification-level>A61K31/713</classification-level><symbol-position> </symbol-position><classification-value> </classification-value></classification-ipc></classification-ipcr>
<application-reference> <document-id><country>EC</country><doc-number>IEPI201728310</doc-number><date>20170509</date></document-id></application-reference>
<priority-claims>
<priority-claim sequence='1' kind='National'><doc-number>62/062,751</doc-number><date>20141010</date><country>US</country></priority-claim>
<priority-claim sequence='2' kind='National'><doc-number>62/147,976</doc-number><date>20150415</date><country>US</country></priority-claim>
<priority-claim sequence='3' kind='National'><doc-number>62/2014,602</doc-number><date>20150904</date><country>US</country></priority-claim>
</priority-claims>
<parties><applicants>
<applicant sequence='1' designation='all' app-type='applicant'><addressbook><name>ALNYLAM PHARMACEUTICALS, INC.</name><address><street>300 Third Street, Cambridge, MA 02142, United States of America</street><country>US</country></address></addressbook></applicant>
</applicants>
<inventors>
<inventor sequence='1' designation='all'><addressbook><name>BELLOTA AGRISOLUTIONS, S.L.</name><address><street>300,third street, Cambridge, MA 02142 United States of America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='2' designation='all'><addressbook><name>LIEBOW, Abigail</name><address><street>300 Third Street, Cambridge, MA 02142, United States of America</street><country>US</country></address></addressbook></inventor>
<inventor sequence='3' designation='all'><addressbook><name>GLAXOSMITHKLINE COLOMBIA S.A.</name><address><street>AVENIDA EL DORADO N° 91-50, CALZADA NORTE, SANTAFE DE BOGOTA D.C. COLOMBIA</street><country>CO</country></address></addressbook></inventor>
<inventor sequence='4' designation='all'><addressbook><name>JOHANNA ORTIZ ZONA FRANCA S.A.S.</name><address><street>CALLE 18 NO 106-46 GREEN S PLAZA PISO 2 CALI VALLE</street><country>CO</country></address></addressbook></inventor>
<inventor sequence='5' designation='all'><addressbook><name>ERBE, David, V.</name><address><street>300 Third Street, Cambridge, MA 02142, United States of America</street><country>US</country></address></addressbook></inventor>
</inventors><agents>
</agents></parties>
<invention-title lang='es'>Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))</invention-title>
</bibliographic-data>
<abstract lang='es'>La invención se refiere a agentes de iARN, por ejemplo, agentes de iARN bicatenarios, que tienen como diana el gen HAO1, y a métodos de uso de tales agentes de iARN para inhibir la expresión de HAO1 y a métodos para tratar sujetos que padecen, por ejemplo, PH1. En la presente se describen agentes de iARN bicatenarios que inhiben la expresión de un gen HAO1 en una célula, tal como una célula en un sujeto, por ejemplo, un mamífero, tal como un ser humano que padece un trastorno asociado con HAO1 y usos de tales agentes de iARN bicatenarios. En ciertos aspectos de la invención, sustancialmente todos los nucleótidos de un iARN de la invención están modificados.</abstract>
</ec-patent-document>
